Double-crane Pharmaceutical To Increase Production Capacity Of Plastic Bottles For Transfusion
This article was originally published in PharmAsia News
Double-crane Pharmaceutical plans to invest over 90 million yuan to establish new lines to manufacture plastic bottles for medical transfusion. Parent Double-crane will loan 81.91 and 28.68 million yuan to its wholly-owned subsidiaries in Anhui and Wuhan, respectively. The Anhui base will set up two new and upgrade one transfusion plastic bottle line, while Wuhan will build one new line. When fully operational, the company's transfusion production lines will reach more than 40, with total manufacturing capacity of 1.3 billion bottles/packages. The production will shift toward more plastic packaging, which gives better profit margins. Double-crane Pharmaceutical aims to build up its transfusion business into the top local brand. (Click here for more - Chinese Language)
You may also be interested in...
Amgen has an open road for its Mvasi bevacizumab biosimilar after Genentech’s appeal to enjoin sales, over a notice of commercial marketing technicality, was denied. The US firm continues to weigh up patent-infringement proceedings in separate actions.
Coronavirus-induced stockpiling and advanced prescribing of medicines has resulted in generics companies across the world registering unprecedented growth during the first quarter of 2020. However, many companies predict sales will level off again in the next quarter and beyond. And as demand fluctuates following the COVID-19 outbreak, companies have started taking precautionary measures to avoid supply-chain disruptions.
Coronavirus Update: Regeneron Races Into Phase III Trial Of Antibodies To Block Coronavirus Infection
Regeneron and NIAID kick off a Phase III prevention trial for antibody cocktail REGN-COV2.